No Clinically Significant Drug-Resistance Mutations in HIV-1 Subtype C-Infected Women After Discontinuation of NRTI-Based or PI-Based HAART for PMTCT in Botswana

被引：2

作者：

Souda, Sajini ^{[1
,2
]}

Gaseitsiwe, Simani ^{[1
]}

Georgette, Nathan ^{[3
]}

Powis, Kathleen ^{[1
,4
,5
]}

Moremedi, Daisy ^{[1
]}

Iketleng, Thato ^{[1
]}

Leidner, Jean ^{[5
]}

Moffat, Claire ^{[1
]}

Ogwu, Anthony ^{[1
]}

Lockman, Shahin ^{[1
,5
,6
]}

Moyo, Sikhulile ^{[1
]}

Mmalane, Mompati ^{[1
]}

Musonda, Rosemary ^{[1
]}

Makhema, Joseph ^{[1
]}

Essex, Max ^{[1
,5
]}

Shapiro, Roger ^{[1
,5
,7
]}

机构：

[1] Botswana Harvard AIDS Inst Partnership HIV Res &, Gaborone, Botswana

[2] Univ Botswana, Sch Med, Dept Pathol, Gaborone, Botswana

[3] Harvard Univ, Cambridge, MA 02138 USA

[4] Massachusetts Gen Hosp, Dept Med & Pediat, Boston, MA 02114 USA

[5] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA

[6] Brigham & Womens Hosp, Dept Med, Div Infect Dis, Boston, MA 02115 USA

[7] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA

来源：

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2013年 / 63卷 / 05期

基金：

美国国家卫生研究院;

关键词：

mother-to-child HIV transmission; highly active anti-retroviral therapy; minor drug-resistance mutations; Botswana; MOTHER-TO-CHILD; COMBINATION ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; TREATMENT INTERRUPTIONS; INITIAL TREATMENT; DOSE NEVIRAPINE; TREATMENT-NAIVE; DOUBLE-BLIND; LAMIVUDINE;

D O I：

10.1097/QAI.0b013e31829308f8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Risk of developing drug resistance after stopping antiretroviral regimens to prevent mother-to-child HIV-1 transmission is unknown. The Mma Bana Study randomized treatment-naive pregnant women with CD4 >= 200 cells per cubic millimeter to receive either abacavir/zidovudine/lamivudine [triple nucleoside reverse transcriptase inhibitor (NRTI) arm] or lopinavir/ritonavir/zidovudine/lamivudine [protease inhibitor (PI) arm]. Drugs were discontinued after 6 months of breastfeeding. One month after discontinuation, 29 NRTI arm samples and 25 PI arm samples were successfully genotyped. No clinically significant antiretroviral resistance mutations were detected. Eight minor resistance mutations were found among 11 (20%) women (3 from NRTI arm and 8 from PI arm), occurring at similar frequencies to those reported in HIV-1 subtype C treatment-naive cohorts.

引用

页码：572 / 577

页数：6

共 2 条

[1] HIV-1 Subtype C Drug Resistance Mutations in Heavily Treated Patients Failing Integrase Strand Transfer Inhibitor-Based Regimens in Botswana
Seatla, Kaelo K.
Maruapula, Dorcas
Choga, Wonderful T.
Ntsipe, Tshenolo
Mathiba, Nametso
Mogwele, Mompati
Kapanda, Max
Nkomo, Bornapate
Ramaabya, Dinah
Makhema, Joseph
Mmalane, Mompati
Mine, Madisa
Kasvosve, Ishmael
Lockman, Shahin
Moyo, Sikhulile
Gaseitsiwe, Simani
VIRUSES-BASEL, 2021, 13 (04):
[2] Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000-2014
Moscona, Roy
Ram, Daniela
Wax, Marina
Bucris, Efrat
Levy, Itzchak
Mendelson, Ella
Mor, Orna
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20

← 1 →